Stock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales

Stock Track

02-27

Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.

The key highlights from Immunocore's earnings report include:

KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.
Progress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.
Advancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.
Initiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.
Cash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.

Immunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1191083799"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191083799\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1191083799?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191083799","market":"us","top_or_hot":-1,"title":"Stock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales","media":"Stock Track","content":"<p>Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.</p>\n\n<p>The key highlights from Immunocore's earnings report include:</p>\n\n<ul>\n<li>KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.</li>\n<li>Progress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.</li>\n<li>Advancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.</li>\n<li>Initiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.</li>\n<li>Cash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.</li>\n</ul>\n\n<p>Immunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-27 00:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.</p>\n\n<p>The key highlights from Immunocore's earnings report include:</p>\n\n<ul>\n<li>KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.</li>\n<li>Progress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.</li>\n<li>Advancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.</li>\n<li>Initiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.</li>\n<li>Cash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.</li>\n</ul>\n\n<p>Immunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMCR","symbol_name":"Immunocore Holdings plc","start_time":0,"source_url":"","article_id":"1191083799","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191083799","pubTimestamp":1740587685,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Immunocore Holdings plc , a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.The key highlights from Immunocore's earnings report include:. KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMCR":"Immunocore Holdings plc"},"translate_title":"股票轨迹Immunocore Holdings飙升5.17%，KIMMTRAK销售强劲，盈利超出预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMCR":1},"content_text":"Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.\nThe key highlights from Immunocore's earnings report include:\n\nKIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.\nProgress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.\nAdvancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.\nInitiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.\nCash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.\n\nImmunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}